Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Pharmaceutical

NJ Innovation Institute and Rutgers Announce Plans to Form the New Jersey Continuous Manufacturing Institute to Advance Pharmaceutical Industry

Newark, NJ, October 17, 2017 — The New Jersey Innovation Institute (NJII), an NJIT Corporation, and Rutgers University announce plans to form the New Jersey Continuous Manufacturing Institute (NJCMI) to advance innovative manufacturing technologies in the pharmaceutical industry.

The NJCMI serves as a center of excellence combining state-of-the-art technologies, infrastructure, facilities and technical expertise to support the development and continuous manufacturing of products for the pharmaceutical industry.

In addition, it provides training, education and workforce development solutions for those who want to expand or gain additional training and expertise in pharmaceutical manufacturing. Continue reading

PhRMA Publishes 2017 Biopharmaceutical Industry Resources; Member Companies Spent $65.5 Billion on R&D in 2016

PhRMA’s 2017 “Chart Pack”

Washington, DC, September 14, 2017 — Did you know that Pharmaceutical Research and Manufacturers of America (PhRMA) member companies invested $65.5 billion in research and development (R&D) in 2016?

Or that combined spending on brand medicines, generics and the supply chain account for 14 percent of total national health spending, with brands accounting for just half of this (7 percent)?

Or that the United States accounts for two thirds of the world’s venture capital investments in high-growth biopharmaceutical startups?

These are but a few of the facts that can be found in PhRMA’s 2017 Biopharmaceutical Research Industry Profile and the 152-page industry chart pack, Biopharmaceuticals in Perspective, which were released July 20.
Continue reading

Vendors Event: HINJ and Somerset County Business Partnership to Host 2017 Life Sciences Vendors Procurement Conference on November 2

New Brunswick, NJ, September 1, 2017 — The HealthCare Institute of New Jersey’s (HINJ) annual Life Sciences Vendors Procurement Conference is scheduled for Thursday, November 2 from 8:00 to 11:30 a.m. at Raritan Valley Community College, Route 28 and Lamington Road, North Branch, NJ.

The event — entitled “How to Do Business with Pharma and Medical Technology Companies” — will be co-sponsored by the Somerset County Business Partnership (SCBP) with support from Eli Lilly and Company and Allergan.

Senator Kip Bateman (R-Somerset) will be the special guest speaker at the event that aims to educate businesses, large and small, on trends on procurement and issues of importance to the industry. Continue reading

NJ Economic Development Authority Board Takes Action to Drive Pharmaceutical Manufacturing Growth

Trenton, NJ, August 13, 2017 — The Board of the New Jersey Economic Development Authority (EDA) took action on August 8 that will help advance one of the key legislative objectives of the Economic Opportunity Act (EOA) — driving growth in targeted industries.

Potential investment in the manufacturing sector was highlighted at EDA Board meeting, as three manufacturers of pharmaceutical products were approved for Grow New Jersey (Grow NJ) tax credits to either locate or expand in New Jersey.

Grow NJ is the main job creation and retention program administered under the EOA. Continue reading

Partnership Between Drug and Glass Companies Means More Jobs for New Jersey

Vineland, NJ, August 2, 2017 — Bill Gallo, Jr. reported on NJBIZ that a collaborative effort among giants in the pharmaceutical and glass industry will mean new jobs in South Jersey, officials say.

Drug manufacturers Merck and Pfizer have joined with Corning Glass in creating a new, stronger glass packaging for injectable drugs, Valor Glass.

Corporate officials say Corning is making an initial investment of $500 million and creating 1,000 new U.S. jobs as the first part of a planned investment of $4 billion and 4,000 new high-tech jobs. Continue reading

FDA Commissioner Delays Layoff Notices and Reassures Staff Congress Will Reauthorize User Fees

FDA Commissioner Scott Gottlieb, M.D.

Washington, DC, July 27, 2017 — Michael Mezher reports on Endpoints News that, in a July 24 email to agency staff, FDA commissioner Scott Gottlieb, M.D., said he will delay issuing layoff notices until after September 30, which is when the agency’s current user fee agreements expire.

Previously, the FDA indicated it could issue layoff notices to thousands of staffers funded by user fees should Congress not act by August 1.

In the email, Gottlieb said he is optimistic the Senate will take up the matter soon and the agency can “reasonably expect” reauthorization to occur before the September 30 deadline. Continue reading

National Science Foundation Study: U.S. Companies Performed 18 Percent of R&D Outside the U.S. in 2013;

Washington, DC, April 18, 2017 — U.S. companies spent $73 billion on research and development (R&D) performed outside the United States in 2013, according to a new report by the National Science Foundation’s National Center for Science and Engineering Statistics.

The total represented 18 percent of U.S. companies’ total R&D performance.  These same companies spent $323 billion on R&D performed within the United States in 2013.

Almost 50 percent of the foreign R&D performance by U.S. companies was in Europe, largely in the United Kingdom and Germany. Continue reading

PhRMA Launches ‘Share the Savings’ Campaign to Urge Payers to Share Negotiated Discounts with Patients

Washington, DC, April 7, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday unveiled “Share the Savings,” a new campaign to educate the public about the lack of rebate pass-through for commercially insured patients with high deductibles and coinsurance.

Robust negotiations between biopharmaceutical companies and health plans result in significant rebates and discounts.

According to a recent study from the Berkeley Research Group, more than a third of the list price for brand medicines is rebated back to payers and the supply chain.  Continue reading

Celebrating Failure in a Tough Drug Industry; As Few as 1 Out of 10,000 Compounds Tested Get FDA Approval

New York, NY, March 9, 2017 — Jonathan D. Rockoff reports in The Wall Street Journal after making the difficult decision to scrap a once-promising drug program, the biotech firm Ironwood Pharmaceuticals in Cambridge, Mass., did something unusual: It gathered to celebrate.

With dozens of staffers in attendance, the “drug wake” at Ironwood featured seven-layer dip, homemade cupcakes and a bittersweet send-off.

“It’s hard to say goodbye, so I won’t,” said Mark Charest, who works on regulatory affairs at the company.  “I’ll say, ‘Thank you—thank you to the peptide.’” Continue reading

ITIF Report: Timely Congressional Reauthorization of Prescription Drug User Fee Act Is Critical for Biomedical Innovation

Washington, DC, March 6, 2017 — As Congress considers reauthorizing the Prescription Drug User Fee Act (PDUFA) this year, policymakers should recognize the foundational role it plays in America’s biomedical ecosystem by supporting life-sciences innovation and speeding cures, argues the Information Technology and Innovation Foundation (ITIF) in a new report.

“User fees help provide the FDA with the resources necessary to make accurate, timely determinations about the safety and efficacy of new drugs,” said Stephen J. Ezell, ITIF’s vice president for global innovation policy and the report’s author. Continue reading